Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Non-Current Liabilities (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $1.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Non-Current Liabilities fell 50.0% year-over-year to $1.0 million, compared with a TTM value of $1.0 million through Mar 2025, down 50.0%, and an annual FY2024 reading of $2.0 million, changed 0.0% over the prior year.
  • Other Non-Current Liabilities was $1.0 million for Q1 2025 at Arcadia Biosciences, down from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.1 million in Q1 2021 and bottomed at $1.0 million in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $2.0 million, with a median of $2.0 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities rose 7.0% in 2021, then tumbled 50.0% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $2.1 million in 2021, then decreased by 3.38% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then crashed by 50.0% to $1.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RKDA at $1.0 million in Q1 2025, $2.0 million in Q4 2024, and $2.0 million in Q3 2024.